Revenue and Profit - Revenue for Q3 2022 reached ¥1,636,515,303.73, an increase of 7.83% year-over-year, while year-to-date revenue totaled ¥5,395,177,444.06, up 16.49% compared to the previous year[7] - Net profit attributable to shareholders for Q3 2022 was ¥141,118,351.11, reflecting a 14.41% increase year-over-year, with a year-to-date net profit of ¥652,257,852.66, up 41.33%[7] - Basic earnings per share for Q3 2022 were ¥0.0962, a 14.39% increase from the same period last year, while year-to-date earnings per share reached ¥0.4445, up 41.34%[7] - Total operating revenue for the period reached ¥5,395,177,444.06, an increase of 16.6% compared to ¥4,631,282,401.56 in the previous period[33] - Net profit for the period was ¥650,063,599.37, representing a 42.3% increase from ¥457,062,547.37 in the same period last year[36] - The total comprehensive income attributable to the parent company was approximately CNY 1,028,077,003.26, an increase from CNY 464,586,111.21 in the previous period[39] - Basic and diluted earnings per share were both CNY 0.4445, up from CNY 0.3145 in the previous period[39] Assets and Liabilities - Total assets as of the end of Q3 2022 amounted to ¥21,469,099,221.29, representing a 12.36% increase from the end of the previous year[7] - The company's total liabilities increased by 61.53% year-over-year, with short-term borrowings reaching ¥3,046,828,803.75[12] - Total liabilities increased to ¥8,997,212,942.94, up 18.6% from ¥7,584,859,851.21 in the previous period[32] - The total equity attributable to shareholders of the parent company reached ¥12,361,047,485.93, an increase from ¥11,411,354,455.88, reflecting an 8.3% growth[32] - The company's goodwill increased to ¥2,396,630,597.70, up from ¥2,152,201,146.76, indicating a growth of 11.4%[29] - Deferred income tax assets rose to ¥135,250,767.58, compared to ¥121,717,732.33 in the previous period, marking an increase of 11.0%[29] Cash Flow - The company reported a significant increase in cash flow from operating activities, with a net cash flow of -¥719,281,089.84 year-to-date, reflecting a decline of 686.10%[7] - The net cash flow from operating activities decreased by 686.10% to -719,281,089.84 RMB compared to the same period last year, primarily due to increased cash payments for goods and services exceeding cash received from sales[17] - The net cash flow from investing activities dropped by 99.77% to 2,353,780.24 RMB, significantly lower than the previous year's high due to the receipt of Kymab equity transfer funds last year[17] - The net cash flow from financing activities increased by 307.43% to 970,216,608.77 RMB, mainly due to a rise in cash received from borrowings[17] - The total cash and cash equivalents decreased by 60.32% to 263,874,379.54 RMB, influenced by the combined reduction in cash flow from operating and investing activities[17] - Cash inflow from operating activities totaled CNY 6,083,780,203.37, compared to CNY 5,014,053,179.06 in the previous period[40] - Cash outflow from operating activities was CNY 6,803,061,293.21, leading to a net cash flow from operating activities of CNY -719,281,089.84, down from CNY 122,722,548.80 in the previous period[40] - Cash inflow from investment activities was CNY 4,584,605,355.61, a decrease from CNY 4,925,011,837.57 in the previous period[43] - Cash outflow from investment activities was CNY 4,582,251,575.37, compared to CNY 3,887,683,914.80 in the previous period[43] - Cash inflow from financing activities was CNY 4,939,819,789.90, up from CNY 2,890,440,715.27 in the previous period[43] - The net cash flow from financing activities was CNY 970,216,608.77, a significant improvement from CNY -467,723,955.63 in the previous period[43] - The ending balance of cash and cash equivalents was CNY 1,743,507,813.58, down from CNY 1,995,176,277.51 in the previous period[43] Inventory and Expenses - Inventory increased by 38.15% year-over-year to ¥6,503,409,988.32, driven by strategic raw material reserves and anticipated market demand growth[12] - Operating costs amounted to ¥4,468,505,243.35, up 8.9% from ¥4,100,533,785.75 in the prior period[33] - Research and development expenses for Q3 2022 were ¥166,593,528.66, a 52.92% increase compared to the same period last year, indicating a focus on innovation[13] - Research and development expenses increased to ¥166,593,528.66, up 53.1% from ¥108,939,733.97 in the previous period[33] - Inventory levels rose significantly to 6,503,409,988.32 RMB from 4,707,548,592.43 RMB, reflecting increased stock levels[26] - The long-term equity investments decreased to 1,062,848,714.35 RMB from 1,146,464,930.04 RMB, indicating a reduction in long-term investment holdings[26] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 26,203, with the top ten shareholders holding significant stakes, including Shenzhen Le Ren Technology Co., Ltd. at 32.31% and Urumqi Jintian Soil Equity Investment Partnership at 27.81%[18] - The cash and cash equivalents as of September 30, 2022, amounted to 2,947,231,848.07 RMB, slightly up from 2,944,257,086.12 RMB at the beginning of the year[26] Other Information - The company has not disclosed any new product developments or market expansion strategies in the current report[24] - The company reported a foreign currency translation difference of CNY 312,215,768.46, compared to CNY 14,691,546.20 in the previous period[39]

Financial Performance - Total revenue for Q3 2022 reached ¥1,636,515,303.73, representing a year-over-year increase of 7.83%[3] - Net profit attributable to shareholders for Q3 2022 was ¥141,118,351.11, up 14.41% compared to the same period last year[3] - The net profit excluding non-recurring gains and losses for Q3 2022 was ¥122,989,129.35, showing a slight decrease of 0.23% year-over-year[3] - Basic earnings per share for Q3 2022 were ¥0.0962, an increase of 14.39% year-over-year[3] - The company achieved a total sales revenue of RMB 5,395.2 million, an increase from RMB 4,631.3 million in the same period last year, representing a growth of 16.6%[13] - Gross profit for the period was RMB 1,740.6 million, compared to RMB 1,456.6 million in the previous year, indicating a growth of 19.5%[13] - Net profit attributable to shareholders was RMB 652.3 million, up from RMB 461.5 million year-on-year, reflecting a growth of 41.3%[13] - Operating profit rose by 50.33% to RMB 841.9 million, driven by increased gross profit and foreign exchange gains[9] - Net profit for the period was ¥650,063,599.37, representing a 42.3% increase from ¥457,062,547.37 in the previous period[27] Cash Flow - Cash flow from operating activities showed a significant decline, with a net cash outflow of ¥719,281,089.84, a decrease of 686.10% compared to the previous year[3] - The net cash flow from operating activities decreased by 686.10% to a negative RMB 719.3 million, primarily due to increased cash payments for goods and services[11] - Cash inflow from operating activities for the current period is 6,083,780,203.37 RMB, up from 5,014,053,179.06 RMB in the previous period, representing an increase of approximately 21.4%[30] - Cash outflow from operating activities for the current period totals 6,803,061,293.21 RMB, compared to 4,891,330,630.26 RMB in the previous period, indicating a significant increase of approximately 39.1%[31] - The net cash flow from operating activities for the current period is -719,281,089.84 RMB, a decrease from 122,722,548.80 RMB in the previous period[31] - Cash inflow from financing activities for the current period is 4,939,819,789.90 RMB, compared to 2,890,440,715.27 RMB in the previous period, indicating an increase of approximately 71.0%[32] - The net cash flow from financing activities for the current period is 970,216,608.77 RMB, a significant improvement from -467,723,955.63 RMB in the previous period[32] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥21,469,099,221.29, reflecting a 12.36% increase from the end of the previous year[3] - The total current assets as of September 30, 2022, amount to ¥12,883,683,738.73, an increase from ¥10,769,653,462.96 at the beginning of the year[22] - Total liabilities rose to ¥8,997,212,942.94, up 18.6% from ¥7,584,859,851.21 in the previous period[25] - The total equity attributable to shareholders reached ¥12,361,047,485.93, an increase of 8.3% from ¥11,411,354,455.88[25] - The total liabilities to equity ratio stands at approximately 0.73, indicating a balanced capital structure[25] Inventory and Borrowings - Inventory increased by 38.15% year-over-year, reaching ¥6,503,409,988.32, attributed to strategic raw material reserves and anticipated market demand growth[6] - Short-term borrowings rose by 61.53% to ¥3,046,828,803.75, primarily due to increased bank loans during the reporting period[6] - The company's short-term borrowings have risen to ¥3,046,828,803.75 from ¥1,886,284,700.56, reflecting an increase of approximately 61.4%[23] Research and Development - Research and development expenses increased by 52.92% to RMB 166.6 million, attributed to direct investment increases[8] - Research and development expenses increased to ¥166,593,528.66, compared to ¥108,939,733.97 in the prior period, reflecting a growth of 53.1%[26] Market Performance - The heparin industry chain business achieved sales revenue of RMB 4,611.3 million, a 13.6% increase from RMB 4,054.5 million in the same period last year[14] - Sales revenue from enoxaparin sodium formulations reached approximately RMB 2,315.2 million, representing a 31.1% growth compared to RMB 1,765.6 million last year, with sales volume increasing by 32.7%[14] - The European market sales volume grew by 26.2%, despite currency fluctuations impacting sales[14] - The U.S. market saw a 144.6% increase in sales volume through a combination of partner and self-operated sales models[14] - Sales from the heparin raw material business amounted to approximately RMB 2,208.6 million, a 1.5% increase from RMB 2,176.0 million last year[14] - CDMO business sales reached approximately RMB 749.9 million, a 37.5% increase from RMB 545.0 million in the previous year[15] Strategic Initiatives - The company continues to strengthen relationships with existing clients and optimize supply chain management to support growth objectives[13] - The company plans to strengthen marketing and market development for enoxaparin sodium formulations, particularly in Europe and the U.S.[17] - The company aims to enhance its supply chain management and maintain cost advantages to improve financial performance amid economic uncertainties[16] - The company will continue to explore new customer opportunities in the CDMO sector and enhance service capabilities in microbiology[17] - The company is committed to optimizing its global industrial chain deployment to achieve sustainable profitability[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 26,203, with the top 10 shareholders holding a combined 78.69% of shares[18] - Shenzhen Le Ren Technology Co., Ltd. holds 32.31% of shares, amounting to 474,029,899 shares, while Urumqi Jintian Soil Equity Investment Partnership holds 27.81% with 408,041,280 shares[19] - The top shareholder relationships indicate that Shenzhen Le Ren Technology Co., Ltd. and Urumqi Jintian Soil Equity Investment Partnership are linked through common partners, Li Li and Li Tan[19]

Financial Performance - Revenue for the six months ended June 30, 2022, was RMB 3,756,335, an increase of 20.7% compared to RMB 3,111,164 for the same period in 2021[18]. - Gross profit for the same period was RMB 1,218,477, representing a gross profit margin of 32.4%, up from 31.4% in 2021[18]. - Profit for the period reached RMB 510,404, a significant increase of 51.6% compared to RMB 336,496 in the prior year[18]. - Profit attributable to equity holders increased by 51.2% to RMB 511.1 million, achieving key production and operational performance targets[26]. - The Group's total comprehensive income for the period was RMB 10,566,836,000 as of June 30, 2022, compared to RMB 10,157,664,000 for the same period in the previous year[143]. - Basic and diluted earnings per share for the six months ended June 30, 2022, were both RMB 0.35, representing an increase of approximately 51.2% from RMB 0.23 in the same period last year[77]. Assets and Liabilities - Total assets as of June 30, 2022, amounted to RMB 21,361,911, an increase from RMB 19,108,177 at the end of 2021[18]. - Total liabilities as of June 30, 2022, were approximately RMB 9,215.9 million, an increase from RMB 7,584.9 million as of December 31, 2021[83]. - The asset-liability ratio as of June 30, 2022, was approximately 43.1%, compared to 39.7% as of December 31, 2021[83]. - Cash and cash equivalents increased to RMB 2,355,848 as of June 30, 2022, compared to RMB 1,479,633 at the end of 2021[18]. Revenue Segmentation - Revenue from the sale of goods reached RMB 3,268.9 million, accounting for 87.0% of total revenue, with a year-on-year increase of 19.4%[61]. - Sales revenue from finished dose pharmaceutical products increased by 41.9% year-on-year, driven by recovery in the European market and expansion in the U.S. and other markets[61]. - Revenue from external customers in the United States increased to RMB 675,882, up from RMB 332,186 in the previous year, reflecting a growth of approximately 103.3%[175]. - Revenue from finished dose pharmaceutical products was RMB 1,601,941, while active pharmaceutical ingredients (API) revenue was RMB 1,610,312 for the six months ended June 30, 2022[182]. Operational Highlights - The company operates a CDMO business through subsidiaries specializing in recombinant pharmaceutical products and gene therapy[21]. - The CDMO business maintained stable growth, supported by a steady increase in orders and improved delivery rates[27]. - The Group's CDMO segment reported revenue of RMB 468,180, and the "others" segment contributed RMB 75,902, leading to a total segment revenue of RMB 6,694,029 before intersegment eliminations[166]. - The Group aims to enhance its CDMO business by improving on-time delivery and success rates, while expanding R&D and production capacity for long-term growth[54]. Market and Product Development - The company is developing a self-discovered proprietary drug candidate currently at the preclinical stage[21]. - Hepalink is developing innovative drug candidates for immune-related diseases, currently in the preclinical stage[24]. - The Group is committed to enhancing the treatment level of thromboembolic diseases in China through product improvements and market structure establishment[36]. - The Group actively participated in over 300 academic conferences to promote low molecular weight heparin education and expand sales channels[36]. Cost and Expenses - Cost of sales rose by RMB 403.6 million to RMB 2,537.9 million, primarily due to increased sales volume during the reporting period[63]. - Selling and distribution expenses rose to RMB 243,563, up from RMB 195,059, reflecting increased operational costs[134]. - Administrative expenses increased to RMB 298,078 from RMB 259,307, indicating higher overhead costs[134]. Financial Management - The Group's capital management focuses on maintaining the ability to provide returns for shareholders while managing its capital structure in response to economic conditions and future capital requirements[78]. - The Group actively uses financial market tools to mitigate foreign exchange risks associated with international sales[79]. - The Group plans to utilize financial market tools to mitigate foreign exchange loss risks and will actively promote internal loan conversion approval processes[82]. Shareholder Information - The Board does not recommend the distribution of an interim dividend for the six months ended June 30, 2022, compared to nil for the same period in 2021[91]. - The Company has no events after the Reporting Period that need to be brought to the attention of shareholders, except for the ongoing impact of the COVID-19 pandemic[89]. - The Company has not disclosed any new strategies or market expansions in the provided content[116]. Compliance and Governance - The Audit Committee reviewed the unaudited consolidated interim results for the six months ended June 30, 2022, confirming compliance with relevant accounting standards and regulations[131]. - The Company has complied with all applicable provisions of the Corporate Governance Code during the reporting period[120]. - The Board consists of three executive Directors and three independent non-executive Directors, ensuring independent views carry significant weight[120].

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[1] - The net profit attributable to shareholders was RMB 300 million, an increase of 20% compared to the same period last year[1] - The company's operating revenue for the first half of 2022 was CNY 3,758,662,140.33, representing a 20.72% increase compared to CNY 3,113,537,181.32 in the same period last year[38] - The net profit attributable to shareholders for the reporting period was CNY 511,139,501.55, a 51.15% increase from CNY 338,158,072.26 year-on-year[38] - The net profit after deducting non-recurring gains and losses was CNY 504,297,490.93, which is a 77.07% increase compared to CNY 284,799,637.39 in the previous year[38] - In the first half of 2022, the company achieved revenue of RMB 3.759 billion, a year-on-year increase of 20.72%, and a net profit attributable to shareholders of RMB 511 million, up 51.15%[77] - The heparin industry chain business grew by 20.62%, generating sales revenue of RMB 3.213 billion[77] - The company's formulation business reported sales revenue of RMB 1.602 billion, reflecting a year-on-year growth of 41.92%[78] Market Expansion and Strategy - The company plans to launch three new products in the next quarter, focusing on innovative drug delivery systems[1] - Future outlook indicates a projected revenue growth of 10-15% for the second half of 2022[1] - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2023[1] - The company is focusing on expanding its market share in Europe with its enoxaparin sodium formulation, which has been approved as a first generic drug[142] - The company is actively enhancing its international drug registration capabilities to expand into emerging markets and increase market share[79] Research and Development - Investment in R&D increased by 18%, totaling RMB 150 million, to enhance product development capabilities[1] - The group has developed a candidate drug for oncology currently in the preclinical stage, with over 20 first-in-class drug varieties covering more than 30 indications through industrial and equity investments[55] - The company has invested in new drug research and development, establishing a pipeline of innovative drugs in various clinical stages[146] - The company is focused on continuous R&D in technology, quality assurance, and new product specifications, collaborating with leading technology firms[199] Risk Management - The company has identified key risks including regulatory changes and market competition, with strategies in place to mitigate these risks[1] - The company faces risks related to product quality, market competition, and reliance on enoxaparin sodium products for revenue[143][144] - The company has significant exposure to foreign exchange risks due to major revenues coming from overseas markets, primarily in euros and US dollars, which may lead to substantial exchange gains or losses[149] - The company aims to effectively hedge foreign exchange market risks through its foreign exchange derivative transactions[125] Environmental and Social Responsibility - The company reported no exceedance of pollution discharge standards at its Nanshan plant, maintaining compliance with environmental regulations[162] - The company is committed to sustainability and environmental responsibility, as evidenced by its adherence to stringent pollution control measures[176] - The company actively responded to the COVID-19 pandemic by donating protective supplies to local communities and providing testing equipment to health centers[193] - The company promotes energy-saving and emission-reduction practices in its operations[196] Corporate Governance - The company has established a robust governance structure to protect the rights of shareholders and creditors, ensuring timely and accurate information disclosure[194] - The company has implemented measures to mitigate foreign exchange losses, including the use of financial market tools and promoting internal loan conversion approvals[149] - The company has experienced changes in its management team, with the appointment of a new CFO following the resignation of the previous one[155] Production and Quality Control - The company operates in the heparin industry, focusing on the production of enoxaparin sodium preparations and raw materials, with a strong emphasis on quality and long-term partnerships with international pharmaceutical companies[49] - The company is committed to providing high-quality, safe, and effective drugs and services to meet unmet clinical needs globally[48] - The company has established two major production bases for heparin sodium raw materials, ensuring stable supply and quality for its international clients[49] - The company emphasizes product quality as a lifeline, implementing a comprehensive quality control system to protect consumer rights[195]

Financial Performance - Revenue for 2021 reached RMB 6,359,786, an increase of 19.6% compared to RMB 5,315,685 in 2020[12] - Profit before tax for 2021 was RMB 222,264, a significant decrease of 83.2% from RMB 1,327,836 in 2020[12] - Profit attributable to owners of the Company for 2021 was RMB 240,788, down 76.5% from RMB 1,024,210 in 2020[12] - Basic earnings per share for 2021 decreased to RMB 0.16 from RMB 0.76 in 2020, reflecting a decline of 78.9%[12] - Earnings attributable to equity holders of the parent were approximately RMB 240.8 million, a decrease of 76.5% year-on-year[17] - Basic earnings attributable to equity holders of the parent, excluding certain impacts, were approximately RMB 557.3 million, representing a decrease of 9.5% compared to the previous year[17] - The Group's financial performance was impacted by high raw material costs and rising operating costs throughout most of 2021[28] - Gross profit for the year 2021 was RMB 1,993.6 million, with a gross profit margin of 31.3%, down from RMB 2,016.8 million and a margin of 37.9% in 2020[71] Assets and Liabilities - Total assets as of 2021 amounted to RMB 19,108,177, a slight increase from RMB 19,025,895 in 2020[13] - Total liabilities for 2021 were RMB 7,584,862, an increase from RMB 7,336,905 in 2020[13] - Equity attributable to shareholders of the Company was RMB 11,411,354 in 2021, a decrease from RMB 11,569,392 in 2020[13] - Cash and bank balances at the end of the period amounted to approximately RMB1,479.6 million, reflecting an increase of approximately 11.2% compared to the same period last year[30] - The net gearing ratio decreased to approximately 22.45% from 24.55% as of December 31, 2020[78] - As of December 31, 2021, the Group's total assets were approximately RMB19,108.2 million, an increase from RMB19,025.9 million as of December 31, 2020[80] Market and Growth Strategies - The Company plans to expand its market presence and invest in new product development to drive future growth[12] - Strategic initiatives include potential mergers and acquisitions to strengthen market position and enhance operational capabilities[12] - Hepalink aims to increase its global market share of heparin finished doses in 2022 while maintaining its leading position in the industry[23] - The company plans to promote the clinical development of existing innovative pharmaceutical projects and enrich its pipeline to enhance competitive advantage[23] - The Group plans to expand its overseas markets and increase its global business scale, particularly solidifying its leading position in the European market[60] Product Development and Innovation - The management highlighted ongoing research and development efforts aimed at enhancing product offerings and technological advancements[12] - The Group has made significant progress in new drug research, including the approval of a global Phase III clinical trial for Oregovomab in Taiwan[19] - The Group's enoxaparin sodium products achieved commercial sales in 43 countries, with over 300% year-on-year growth in non-European and U.S. regions[19] - The innovative drugs sector has been a key focus, with a 20% increase in product pipeline advancements since last year[86] - The company has invested $50 million in research and development for new technologies in the pharmaceutical sector[86] Sales and Marketing - Revenue from finished dose pharmaceutical products increased by 74.6% compared to the same period last year, contributing to over 50% of total revenue[17] - The Group strengthened its sales and marketing team in China to capitalize on opportunities arising from healthcare reform policies[28] - The Group's proactive sales strategy in Europe led to an increase in bidding contracts and new sales regions during the reporting period[39] - The Group has established a local marketing team in Europe to enhance localized sales strategies and improve market feedback integration[39] Corporate Governance and Compliance - The Company has complied with all applicable code provisions in the Corporate Governance Code during the Reporting Period[171] - The Board of Directors consists of 8 members, including 4 executive directors, 1 non-executive director, and 3 independent non-executive directors[178] - The Company has maintained at least three independent non-executive directors, representing one-third of the board, fulfilling the listing rules requirements[180] - The Company has a clear division of responsibilities between the Chairman and the General Manager, enhancing governance effectiveness[180] Risks and Challenges - The company faces risks related to the quality standards of its products, which could adversely affect its business and reputation[173] - Fluctuations in raw material prices may have a significant adverse effect if cost increases cannot be passed on to customers[173] - Sales of enoxaparin sodium injection products are dependent on government reimbursement policies, which could limit revenue generation[173] Employee and Stakeholder Relations - The Group had 2,106 employees as of December 31, 2021, with total staff costs approximately RMB 684.6 million, a decrease from RMB 699.5 million in 2020[165] - Employee remuneration includes salary, bonuses, and allowances, designed to reward performance against specified criteria[166] - The Group made donations totaling RMB 2.7 million during the Reporting Period[171] Future Outlook - The Group expects China's GDP growth in 2022 to exceed the potential growth rate, marking a significant improvement in business segments and profitability compared to 2021[60] - The Group aims for solid and sustainable revenue growth, with a focus on enhancing financial performance and corporate value in the upcoming year[60] - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[90]

Revenue and Profit - Revenue for Q1 2022 reached ¥1,910,323,745.74, a 50.67% increase compared to ¥1,267,876,796.45 in the same period last year[5] - Net profit attributable to shareholders was ¥234,943,371.65, reflecting a 63.74% increase from ¥143,483,266.73 year-on-year[5] - Basic earnings per share increased to ¥0.1601, up 63.70% from ¥0.0978 in the same period last year[5] - Operating profit for Q1 2022 was ¥283,490,135.32, a 55.54% increase from ¥182,256,245.68 in the same period last year[11] - Net profit for the quarter was CNY 235,239,208.83, compared to CNY 142,677,904.44 in the same period last year, reflecting a growth of approximately 64.7%[30] - Total comprehensive income reached ¥230,706,330.71, up from ¥150,660,916.07 in the previous period, indicating a significant increase[40] - Basic and diluted earnings per share improved to ¥0.1601 from ¥0.0978, reflecting a growth of approximately 63.5%[42] - The comprehensive income attributable to the parent company was ¥229,877,989.65, up from ¥151,343,035.84, indicating strong performance[40] Cash Flow - The net cash flow from operating activities was -¥1,378,827.28, a significant decline of 100.33% compared to ¥419,806,687.16 in the previous year[5] - Cash inflow from operating activities was ¥1,797,252,829.50, compared to ¥1,622,062,741.93 in the prior period, showing an increase of about 10.8%[44] - Cash inflow from investment activities totaled ¥1,358,175,685.65, slightly up from ¥1,286,550,262.68, while net cash flow from investment activities decreased to -¥88,020,516.24 from ¥297,313,031.90[49] - Cash inflow from financing activities was ¥1,426,538,930.97, an increase from ¥1,029,254,863.37, with net cash flow from financing activities rising to ¥616,763,600.63 from ¥72,788,524.98[49] - The ending balance of cash and cash equivalents was ¥1,997,256,205.52, down from ¥2,099,624,973.72 in the previous period[49] - The company reported a net increase in cash and cash equivalents of ¥517,622,771.48, compared to ¥769,379,717.55 in the prior period[49] Assets and Liabilities - Total assets at the end of the reporting period were ¥20,130,476,736.54, a 5.35% increase from ¥19,108,175,266.78 at the end of the previous year[5] - Current liabilities rose to CNY 5,732,113,230.57, up from CNY 4,791,469,653.07, which is an increase of approximately 19.7%[25] - Long-term borrowings decreased to CNY 1,239,870,555.32 from CNY 1,388,037,756.96, showing a reduction of about 10.7%[25] - The total liabilities increased to CNY 8,376,454,990.26 from CNY 7,584,859,851.21, reflecting a growth of about 10.4%[25] - The equity attributable to shareholders of the parent company rose to CNY 11,641,232,445.53 from CNY 11,411,354,455.88, an increase of approximately 2.0%[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 29,871[12] - Shenzhen Le Ren Technology Co., Ltd. holds 32.31% of shares, totaling 474,029,899 shares[12] - Urumqi Jintian Soil Equity Investment Partnership holds 27.81% of shares, totaling 408,041,280 shares[12] - HKSCC Nominees Limited holds 15.00% of shares, totaling 220,044,480 shares[12] Expenses and Investments - The company reported a significant increase in sales expenses, which rose by 35.67% to ¥120,294,534.92 due to higher marketing costs[8] - Investment income showed a drastic decline of 194.46%, resulting in a loss of ¥30,599,687.00 compared to a profit of ¥32,393,930.46 in the previous year[8] - Research and development expenses for the quarter were CNY 20,883,937.48, compared to CNY 17,792,316.55 in the previous year, indicating an increase of approximately 17.5%[30] - The company’s long-term equity investments decreased to RMB 1,109,635,762.98 from RMB 1,146,464,930.04, a decline of about 3%[19] Future Plans and Strategies - The company plans to issue bonds up to RMB 1.5 billion to support business development[16] - The first quarter report indicates a focus on expanding market presence and enhancing product development strategies[21]

Financial Performance - The company's operating revenue for Q1 2022 was CNY 1,910,323,745.74, representing a 50.67% increase compared to CNY 1,267,876,796.45 in the same period last year[3] - Net profit attributable to shareholders for Q1 2022 was CNY 234,943,371.65, a 63.74% increase from CNY 143,483,266.73 year-on-year[3] - Basic and diluted earnings per share for Q1 2022 were CNY 0.1601, up 63.70% from CNY 0.0978 in the same period last year[3] - The gross profit for the period was RMB 579.2 million, up from RMB 418.0 million year-on-year, reflecting a strong growth in profitability[12] - Net profit attributable to shareholders was RMB 234.9 million, compared to RMB 143.5 million in the previous year, marking a 63.7% increase[12] - The total comprehensive income for the current period was ¥230,706,330.71, compared to ¥150,660,916.07 in the previous period, reflecting an increase of approximately 53.1%[26] Cash Flow - The net cash flow from operating activities was negative CNY 1,378,827.28, a decline of 100.33% compared to CNY 419,806,687.16 in the previous year[3] - The cash flow from operating activities showed a significant decline, with a net outflow of RMB 1,378,827.28 compared to a net inflow of RMB 419,806,687.16 in the same period last year, a decrease of 100.33%[11] - The cash flow from financing activities increased by 747.34%, reaching RMB 616,763,600.63, primarily due to a rise in net borrowings[11] - The cash flow from financing activities generated a net inflow of ¥616,763,600.63, compared to a net inflow of ¥72,788,524.98 in the previous period, indicating a substantial increase[30] - The cash flow from investing activities resulted in a net outflow of ¥88,020,516.24, contrasting with a net inflow of ¥297,313,031.90 in the previous period[29] Operating Costs and Expenses - The company's operating costs for Q1 2022 were CNY 1,331,158,955.65, reflecting a 56.63% increase from CNY 849,901,135.30 year-on-year, primarily due to increased sales volume[9] - Sales expenses increased by 35.67% to CNY 120,294,534.92, attributed to higher marketing costs during the reporting period[9] - Total operating costs for the current period were RMB 1,657,045,547.09, up from RMB 1,129,172,329.84 in the previous period, indicating an increase of about 46.6%[24] Assets and Liabilities - Total assets at the end of Q1 2022 were CNY 20,130,476,736.54, a 5.35% increase from CNY 19,108,175,266.78 at the end of the previous year[3] - Accounts payable increased by 39.43% to CNY 537,885,101.63, mainly due to higher raw material purchases during the reporting period[7] - The company's cash and cash equivalents at the end of the period amounted to RMB 3,471,470,490.96, compared to RMB 2,944,257,086.12 at the beginning of the year, reflecting a growth of approximately 17.9%[20] - Accounts receivable increased to RMB 1,649,294,941.30 from RMB 1,518,444,482.00, marking a rise of about 8.6%[20] - Inventory levels rose to RMB 5,064,439,320.27 from RMB 4,707,548,592.43, which is an increase of approximately 7.6%[20] - Current liabilities increased to RMB 5,732,113,230.57 from RMB 4,791,469,653.07, representing a growth of approximately 19.7%[22] Market and Strategic Initiatives - The company plans to continue expanding its market presence and enhancing its sales capabilities, particularly in Europe and the US, to offset challenges from geopolitical tensions[13] - The company aims to steadily increase core business sales while capitalizing on favorable raw material prices to significantly improve performance[15] - The company plans to enhance internal collaboration and accelerate the construction of financial and human resource shared centers, as well as the digital transformation of marketing strategies[15] - The company is committed to improving global supply chain efficiency and management, continuously enhancing quality and optimizing costs[15] - The company will actively strengthen its R&D capabilities and connect with global innovative drug development to promote the expansion of its innovative drug field[15] - The company will continue to focus on international market strategies, particularly in Europe, the United States, and non-European and American markets, while actively supporting the normalization of development in the Chinese market[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 29,871, with the top ten shareholders holding a combined 82.76% of shares[16] - Shenzhen Le Ren Technology Co., Ltd. held 32.31% of shares, while Urumqi Jintian Soil Equity Investment Partnership held 27.81%[16] Bond Issuance - The company plans to issue bonds to professional investors with a total scale not exceeding RMB 1.5 billion, which was approved by the board on December 10, 2021[19] - The bond issuance was registered and approved by the China Securities Regulatory Commission in March 2022, with listing on the Shenzhen Stock Exchange on April 8, 2022[19] Other Financial Metrics - The company recorded a net loss of RMB 4,532,878.12 in other comprehensive income, a significant decrease of 156.78% compared to a net gain of RMB 7,983,011.63 in the same period last year[10] - The company reported a foreign exchange loss of ¥9,741,485.63, compared to a loss of ¥20,528,526.49 in the previous period, indicating an improvement in foreign exchange impact[30] - The first quarter report has not been audited[31]

Financial Performance - The company's audited revenue decreased by 62.97 million yuan compared to the preliminary earnings report, representing a reduction of nearly 1%[6] - The company's operating revenue for 2021 was ¥6,365,177,483.41, an increase of 19.38% compared to ¥5,332,074,875.27 in 2020[33] - The net profit attributable to shareholders for 2021 was ¥240,787,578.67, a decrease of 76.49% from ¥1,024,209,839.93 in 2020[33] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥90,112,059.27, down 84.78% from ¥592,007,482.48 in 2020[33] - The net cash flow from operating activities was -¥6,629,319.80, a decline of 117.78% compared to ¥37,283,625.07 in 2020[33] - The basic and diluted earnings per share for 2021 were both ¥0.1641, a decrease of 78.32% from ¥0.7568 in 2020[33] - The total assets at the end of 2021 were ¥19,108,175,266.78, an increase of 0.43% from ¥19,025,894,654.11 at the end of 2020[33] - The net assets attributable to shareholders at the end of 2021 were ¥11,411,354,455.88, a decrease of 1.37% from ¥11,569,392,530.92 at the end of 2020[33] - The company reported a significant decline in net profit in the fourth quarter of 2021, with a loss of -¥220,718,075.50 compared to profits in previous quarters[38] Dividend and Shareholder Relations - The board proposed a cash dividend of 0.35 yuan per 10 shares (including tax), based on a total of 1,467,296,204 shares[5] - The company plans to maintain the total distribution amount unchanged, adjusting the per-share distribution ratio if the share capital changes before implementation[5] - The company expressed sincere apologies to investors for the discrepancies in the financial data reported[8] - The company acknowledged that the differences between audited financial data and preliminary reports were primarily due to non-core business factors, which had a minimal impact on the main business results for 2021[8] Investment and Assets - The company has invested in TPG Biotechnology Partners IV, L.P. and TPG Biotechnology Partners V, L.P., which are industry funds[19] - The company holds stakes in Kymab Group Limited, Curemark LLC, Resverlogix Corp., OncoQuest Inc., Aridis Pharmaceuticals, Inc., and HighTide Therapeutics, Inc.[19] - The company made a significant equity investment of CNY 79,831,733.63 in Curemark LLC, acquiring a 4.20% stake in the new drug development for enzyme preparations[130] - The company reported a total of CNY 3,195,595,033.59 in financial assets at the beginning of the period, with a net change of CNY -5,183,345.49 during the period[125] - The company’s financial assets included trading financial assets of CNY 980,909,046.46 at the end of the period, after accounting for purchases and sales[125] Research and Development - Research and development expenses increased by 38.18% year-on-year, primarily due to increased investment in R&D projects[107] - The number of R&D personnel increased to 332 in 2021, up 13.70% from 292 in 2020[110] - R&D investment amounted to ¥245,824,660.32 in 2021, representing a 49.90% increase from ¥163,994,431.96 in 2020[110] - The proportion of R&D investment to operating revenue rose to 3.86% in 2021 from 3.08% in 2020, an increase of 0.78%[110] Market and Product Development - The company is focusing on innovation and transformation in response to national policies promoting drug price reductions and the normalization of centralized procurement[46] - The company operates in the heparin industry chain, with main products including enoxaparin sodium preparations and heparin raw materials, serving both domestic and international markets[48] - The company has developed approximately 200 different molecular structures in its CDMO business, supporting over 300 clinical trials and maintaining high customer loyalty and industry referral rates[52] - The company holds over 20 first-in-class drug candidates across more than 30 indications, with five indications in global Phase III clinical trials and 18 in Phase II[53] Risk Management - The company has established risk control mechanisms to manage foreign exchange derivative trading risks effectively[146] - The company faces risks including product quality issues due to complex production processes, which could lead to medical accidents[171] - The heparin raw material drug industry is highly competitive, with the company facing challenges from both original and generic brands in the European market[172] - The company relies heavily on two main products: enoxaparin sodium and heparin sodium API, making it vulnerable to various market pressures[173] Corporate Governance - The board of directors consists of 7 members, including 3 independent directors, meeting the legal requirements for governance structure[186] - The company has implemented a transparent performance evaluation and incentive mechanism for directors, supervisors, and senior management[186] - The company emphasizes investor relations management, ensuring effective communication and interaction with investors[189] - The company has not engaged in any related party transactions or provided guarantees for the controlling shareholder or its subsidiaries during the reporting period[185] Strategic Outlook - The company plans to expand into the EU and global markets with the unutilized raised funds[148] - The company aims to enhance financial stability by mitigating the adverse effects of significant exchange rate fluctuations[146] - The company plans to strengthen its leading position in the heparin industry chain, focusing on the European, American, and Chinese markets[166] - The company is committed to investing in innovative drugs to address various health conditions, including cardiovascular diseases and liver diseases[164]

Financial Performance - The company's audited revenue decreased by 62.97 million yuan compared to the preliminary report, representing a nearly 1% reduction due to adjustments made by auditors based on revenue cutoff differences[6]. - The company reported a total revenue of RMB 1.5 billion for the fiscal year 2021, representing a year-over-year increase of 15%[22]. - The company's operating revenue for 2021 was ¥6,365,177,483.41, an increase of 19.38% compared to ¥5,332,074,875.27 in 2020[34]. - The net profit attributable to shareholders for 2021 was ¥240,787,578.67, a decrease of 76.49% from ¥1,024,209,839.93 in 2020[34]. - The net profit after deducting non-recurring gains and losses was ¥90,112,059.27, down 84.78% from ¥592,007,482.48 in 2020[34]. - The net cash flow from operating activities was -¥6,629,319.80, a decline of 117.78% compared to ¥37,283,625.07 in 2020[34]. - The total operating revenue for 2021 was approximately ¥6.37 billion, representing a year-over-year increase of 19.38% from ¥5.33 billion in 2020[91]. - The pharmaceutical manufacturing sector accounted for ¥6.36 billion, or 99.98% of total revenue, with a year-over-year growth of 19.38%[91]. - The company's international revenue reached approximately ¥5.81 billion, accounting for 91.24% of total revenue, with a growth of 20.96% year-over-year[91]. Investment and R&D - The company is investing RMB 200 million in R&D for new drug development, focusing on innovative therapies for rare diseases[22]. - The company’s R&D expenses increased by 38.18% year-on-year, totaling ¥221.10 million in 2021, primarily due to increased investment in R&D projects[108]. - The number of R&D personnel increased to 332 in 2021, up 13.70% from 292 in 2020[111]. - R&D investment amounted to ¥245,824,660.32 in 2021, representing a 49.90% increase from ¥163,994,431.96 in 2020[111]. - The company has increased investment in new drug development, establishing a pipeline of innovative drugs in various clinical stages[175]. Market Expansion and Strategy - Future guidance estimates a revenue growth of 10-15% for the next fiscal year, driven by new product launches and market expansion efforts[22]. - Market expansion efforts include entering two new countries in Europe, aiming for a 5% market share within the first year of operation[22]. - The company is focusing on strategic partnerships with international firms to leverage their distribution networks and increase market penetration[22]. - The company plans to enhance its CDMO services, targeting a 25% increase in contract manufacturing revenue over the next two years[22]. - The company aims to enhance its sales and marketing network in the EU and other global markets, including China, to improve development and production capabilities[155]. Challenges and Risks - The company faced challenges in the audit process due to the pandemic, affecting the collection and preparation of necessary documents[6]. - The company highlighted that the main factors causing discrepancies in net profit were related to investment income losses and impairment of investment project-related assets, which are not related to core business operations[9]. - The company faces risks including product quality, market competition, and reliance on core products, which could adversely affect revenue and profitability[171][172][173]. - The company acknowledges potential adverse effects from outbreaks of infectious diseases on its supply chain and overall business operations[179]. Corporate Governance - The company has established a complete independent business system, ensuring independence in operations, personnel, assets, and finance from its controlling shareholder[191]. - The board of directors consists of 7 members, including 3 independent directors, meeting the legal requirements[186]. - The company strictly adheres to information disclosure regulations, ensuring transparency and fairness in communication with investors[189]. - There were no incidents of the controlling shareholder interfering in the company's operations or decision-making during the reporting period[185]. - The company has maintained a robust internal control system to ensure compliance with relevant laws and regulations[185]. Shareholder Engagement - The company held an earnings conference call on April 28, 2021, to discuss its financial performance with institutional investors[181]. - The annual shareholder meeting on May 26, 2021, had a participation rate of 68.18%[194]. - The first extraordinary shareholder meeting on September 28, 2021, had a participation rate of 69.17%[194].

Revenue and Profit - The company's revenue for Q3 2021 reached ¥1,517,745,220.24, representing a 71.83% increase year-over-year[4] - Net profit attributable to shareholders was ¥123,347,581.91, a decrease of 3.29% compared to the same period last year[4] - The net profit excluding non-recurring gains and losses was ¥123,277,703.12, showing a 21.40% increase year-over-year[4] - Revenue for the period reached CNY 4,631,282,401.56, an increase of 30.74% compared to CNY 3,542,478,922.83 in the same period last year, driven by growth in formulation business and heparin sodium sales[11] - Net profit for the period was CNY 457,062,547.37, down 35.30% from CNY 706,425,192.83 in the previous year[11] - The total profit for the period was CNY 553,666,240.92, a decrease of 34.69% compared to CNY 847,806,788.63 in the previous year[11] - Net profit attributable to the parent company was ¥461,505,654.17, down 34.8% from ¥708,597,054.96 in the previous period[31] - The company reported a total comprehensive income attributable to the parent company of ¥464,586,111.21, down from ¥590,339,643.68 in the previous period[33] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥122,722,548.80, reflecting a significant increase of 194.51%[4] - Cash flow from operating activities improved to CNY 122,722,548.80, a 194.51% increase compared to a negative cash flow of CNY -129,851,048.90 last year[11] - Cash flow from investing activities was CNY 1,037,327,922.77, a 167.45% increase from CNY -1,537,910,388.39, mainly due to cash recovered from investments[11] - The net cash flow from operating activities was $122.72 million, a significant improvement from a negative cash flow of $129.85 million in the previous period[37] - The net cash flow from investment activities was $1.04 billion, recovering from a negative cash flow of $1.54 billion in the previous period[37] - Cash inflow from the recovery of investments was $2.43 billion, a significant increase from $163.81 million in the previous period[37] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥19,265,415,690.14, a 1.26% increase from the end of the previous year[4] - The company's cash and cash equivalents increased by 38.41% to ¥3,754,392,520.03 compared to the previous year-end[7] - Inventory levels rose by 31.27% to ¥4,158,961,510.52, attributed to increased stock in line with sales growth trends[7] - Total liabilities increased, with accounts payable rising by 51.15% to CNY 361,571,598.26, attributed to higher raw material purchases[11] - Contract liabilities surged by 80.73% to CNY 479,013,672.13, mainly due to increased prepayments for CDMO services[11] - The total liabilities of the company were RMB 7,443,374,575.00, compared to RMB 7,336,904,566.95 in the previous period[25] - The company's total equity was RMB 11,822,041,115.14, reflecting a slight increase from RMB 11,688,990,087.16[25] Research and Development - Development expenditures surged by 92.03% to ¥28,952,599.77, primarily due to R&D projects at subsidiaries[7] - R&D expenses increased by 56.96% to CNY 108,939,733.97, reflecting higher direct investment in research and development[11] - Research and development expenses rose to ¥108,939,733.97, up 56.9% from ¥69,407,687.52 in the previous period[28] Investment Income - The company reported a significant decrease in investment income, down 91.02% to CNY 26,785,894.69, due to lower returns from long-term equity investments[11] - The company experienced a decrease in investment income, reporting ¥26,785,894.69 compared to ¥298,214,815.65 in the previous period[28] Earnings Per Share - Basic and diluted earnings per share decreased to ¥0.3145 from ¥0.5467 in the previous period[34]